Dexcom puts up new data in Type 2 diabetes, teases upcoming G7 sensor
To follow up on what it’s described as its “best year ever,” Dexcom has accelerated the development of the newest version of its mainstay continuous glucose monitor in 2021—and delivered new clinical data showing CGM systems can provide significant benefits to patients with Type 2 diabetes, which the company has pegged as a major growth market.